BlueRock Therapeutics
238 Main Street, 3rd Floor
Cambridge
MA
02142
United States
Tel: 1-857-299-7589
Website: https://bluerocktx.com/about/
Email: hr@bluerocktx.com
About BlueRock Therapeutics
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications.
BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.
BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine.
Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us on our website to learn about rewarding career opportunities.
Our CEO, Seth Ettenberg, talking about the importance of Community at BlueRock.
51 articles about BlueRock Therapeutics
-
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story. -
BlueRock Therapeutics Establishes R&D Site in New York City and Formalizes Collaboration with Memorial Sloan Kettering Cancer Center
4/17/2018
Company Receives $1 Million Incentive Through Economic Development Initiative of New York State and Empire State Development
-
BlueRock Therapeutics, which has locations in Toronto, NYC and Cambridge, Mass., rocketed to existence in December 2016 with $225M in venture funding to focus on regenerative medicine, using iPSC therapies. -
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015. -
BlueRock Therapeutics Announces Appointment of Derek Hei, Ph.D. as Senior VP, Manufacturing, Quality and Regulatory
12/1/2017
Dr. Hei brings to BlueRock over twenty years of experience developing breakthrough cell and gene therapies from research through clinical trials.
-
BlueRock was founded in 2016 when Versant Ventures and Bayer invested $225 million in a Series A financing. -
BlueRock Therapeutics And Universal Cells Enter Collaboration And License Agreement To Generate Gene-Edited iPS Cell Lines
10/3/2017
-
BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership
8/17/2017
-
BlueRock Therapeutics Names a New CEO, CTO
6/27/2017
-
VistaGen Grants Exclusive Sublicense Of Cardiac Stem Cell Technologies To BlueRock Therapeutics
12/14/2016
-
Bayer, Versant Ventures Launch BlueRock Therapeutics With $225 Million to Focus on Stem Cell R&D
12/12/2016